Provider review
Hims & Hers tirzepatide review
What Hims & Hers charges, what is included, who prescribes, which pharmacy fills it, where it operates — and how much of that we confirmed ourselves rather than took from the website.
Read on Hims & Hers’s own pages on November 21, 2026: no compounded tirzepatide. It scores 48/100 under our written v4.1 scoring guide, #19 of 22 programs scored, with an open FDA warning letter (716567).
What is distinctive about this programme
The membership is the story
At $149 a month, the Hims and Hers membership equals or exceeds the medication price on their lowest-cost brand option. Oral Wegovy tablets at $149 medication become $298 all-in — double.
For comparison, the identical oral Wegovy tablets are $149 direct from NovoCare with no membership at all. A patient buying through the platform is paying $1,788 a year for the service layer.
The $39 first-month membership is introductory and rises to $149.
Where it is competitive, and where it is not
At $348 all-in for the Wegovy pen and $448 for Zepbound, Hims and Hers sit above PlushCare's $319 for Zepbound and well above manufacturer-direct pricing. Our dataset also flags one listing — a Hers KwikPen price — as unconfirmed, because Lilly's vial-only self-pay programme does not include the pre-filled KwikPen. Verify at checkout.
Hers also lists brand Mounjaro at $1,899 medication plus $149 membership, or $2,048 all-in — the highest single figure in our entire dataset. No manufacturer self-pay programme exists for Mounjaro, but Zepbound is the identical molecule at $299 to $449 direct.
What the membership buys
Ongoing clinical access, messaging and a consumer platform many patients already use for other categories. Whether that is worth $1,788 a year alongside medication is a judgement, but it should be made with the manufacturer-direct price in view.
Show this figure as a table
| Item | Value | Evidence |
|---|---|---|
| Semaglutide brand oral, FDA-approved | $298 | Provider-reported |
| Tirzepatide brand injectable, FDA-approved | $2,048 | Provider-reported |
Where it holds up
- Established platform with broad clinical access and messaging
- Same price at all doses on some brand products
- Wide range of brand options in one place
Where it does not
- $149 monthly membership doubles the cost of the cheapest brand option
- Oral Wegovy at $298 all-in against $149 direct from NovoCare
- One KwikPen listing is unconfirmed against Lilly's vial-only self-pay programme
- Brand Mounjaro at $2,048 all-in is the highest figure in our dataset
- First-month membership rate is introductory
- Figures are third-party reported and not yet captured by us
| Field | Position |
|---|---|
| Membership | Separate and required |
| Dose structure | Escalates with dose or not established |
| Lowest captured figure | $298/mo, month-to-month |
| Evidence status | Third-party reported, pending our own capture |
| Pharmacy named to us | No — provider-reported only |
| Category | Points |
|---|---|
| Pricing transparency | 20 |
| Total annual cost | 20 |
| Clinical oversight | 15 |
| Pharmacy transparency | 15 |
| Support | 10 |
| Regulatory disclosure | 10 |
| Accessibility | 10 |
Pricing, all-in
Plan total and monthly equivalent are calculated by us from the provider's published figures, using the same formula applied to every provider on this site. A price is only a price once the required fees are inside it.
| Provider | Program | Formulation | Dose coverage | Medication | Required fees | All-in monthly | Price type | Evidence | Captured |
|---|---|---|---|---|---|---|---|---|---|
| Hims | month_to_month | brand oral, FDA-approved | not recorded | $298 | not verified | $298 | Recurring | Provider-reported | 2026-07-06 |
| Hers | month_to_month | brand injectable, FDA-approved | not recorded | $2,048 | not verified | $2,048 | Recurring | Provider-reported | 2026-07-06 |
How this sits against the market
The July 2026 all-provider chart that stood here has been retired. Current first-party prices for 28 compounded tirzepatide programs (read October 15, 2026; NexLife November 20, 2026) are on the price index.
Show this figure as a table
| Component | Amount |
|---|---|
| Medication | not captured |
| Membership | not captured |
| Shipping | not captured |
| Dose surcharge | not captured |
| Consultation | not captured |
| Labs | not captured |
| All-in total | not captured |
| Cost component | Inside the advertised figure? | Charged anyway? |
|---|---|---|
| Medication | yes | yes |
| Membership or program fee | no | not verified |
| Shipping | no | not verified |
| Higher-dose surcharge | no | not verified |
| Initial consultation | no | not verified |
| Required laboratory work | no | not verified |
| Cancellation or restocking terms | no | not verified |
This chart stays empty until two or more dated captures exist. Historical values are never estimated or backfilled from a provider's current page.
Show this figure as a table
| Item | This provider | Category median |
|---|---|---|
| All-in monthly | not captured | not captured |
| Membership fee | not captured | not captured |
| Rubric score | not captured | not captured |
What is included, and what is not
Where it holds up
- nothing verified yet
Where it does not
- nothing verified yet
Where it operates
State availability is verified against the provider's own checkout or a support confirmation, state by state, with a capture date. A provider serving forty states is not nationwide, and we do not describe it that way.
Show this figure as a table
| Status | Records | Share |
|---|---|---|
| Researched and verified | 0 | 0% |
| Not yet researched | 51 | 100% |
Pharmacy and fulfilment
What changed
Show this figure as a table
| No events recorded. |
- no entriesNothing has changed yet because nothing has been published yet. Entries appear here when a verified figure, score or conclusion changes, never for a typo fix.
How this compares to the category
Once enough providers are scored, this section reports where Hims & Hers sits against the median for each rubric category, not against a hand-picked competitor.
| Question | Worth | Their answer | Status |
|---|---|---|---|
| Pharmacy traceability and quality disclosures | 15 pts | not verified | Not answered Verification pending |
| Clinical oversight and care continuity | 20 pts | not verified | Not answered Verification pending |
| State access and operational reliability | 10 pts | not verified | Not answered Verification pending |
| Cancellation, billing and support transparency | 10 pts | not verified | Not answered Verification pending |
Questions readers actually ask
Is Hims & Hers the cheapest option?
Read on its own page on November 21, 2026: no compounded tirzepatide; Zepbound vials or KwikPen ‘from $299/mo’ plus the required Weight Loss Membership ($39 the first month, then $149 a month); the page also lists Zepbound at $1,899 a month.
Is compounded tirzepatide the same as Zepbound?
Hims & Hers scores 48/100 under the written v4.1 scoring guide, #19 of 22 programs scored from pages read November 20–21, 2026. Its weakest category is pharmacy transparency (0 of 15).
Related on this site
- All provider reviewsProviders
- NexLife Tirzepatide ReviewProviders
- Ro Body Tirzepatide ReviewProviders
- Mochi Health Tirzepatide ReviewProviders
- How rankings are computedCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- Mounjaro vs ZepboundPillar / Money
- Zepbound vs MounjaroComparisons
- Tirzepatide Cost in 2026Pillar / Money
Related coverage
GLP-1 Tirzepatide Review. “Hims & Hers Tirzepatide Review.” S.J Partners LLC, 2026-07-26. https://glptirzepatidereview.com/providers/hims-hers/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.